Your browser doesn't support javascript.
loading
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.
Yatham, L N; Beaulieu, S; Schaffer, A; Kauer-Sant'Anna, M; Kapczinski, F; Lafer, B; Sharma, V; Parikh, S V; Daigneault, A; Qian, H; Bond, D J; Silverstone, P H; Walji, N; Milev, R; Baruch, P; da Cunha, A; Quevedo, J; Dias, R; Kunz, M; Young, L T; Lam, R W; Wong, H.
Afiliação
  • Yatham LN; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Beaulieu S; Douglas Hospital, McGill University, Montreal, QC, Canada.
  • Schaffer A; Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada.
  • Kauer-Sant'Anna M; Bipolar Disorder Program and Laboratory of Molecular Psychiatry, National Institute for Translational Medicine, INCT-TM, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Kapczinski F; Bipolar Disorder Program and Laboratory of Molecular Psychiatry, National Institute for Translational Medicine, INCT-TM, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Lafer B; Bipolar Research Program, Department and Institute of Psychiatry, University of São Paulo Medical School, Sao Paulo, Brazil.
  • Sharma V; Department of Psychiatry, Western University, London, ON, Canada.
  • Parikh SV; Department of Psychiatry, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Daigneault A; Department of Psychiatry, Université de Montréal, Montreal, QC, Canada.
  • Qian H; Centre for Health Evaluation & Outcome Sciences, St. Paul's Hospital, Vancouver, BC, Canada.
  • Bond DJ; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Silverstone PH; Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
  • Walji N; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Milev R; Department of Psychiatry, Providence Care, Queen's University, Kingston, ON, Canada.
  • Baruch P; Institut universitaire en santé mentale de Québec, Quebec, QC, Canada.
  • da Cunha A; Hospital Universitario de Santa Maria, Santa Maria, Brazil.
  • Quevedo J; Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, Brazil.
  • Dias R; Bipolar Research Program, Department and Institute of Psychiatry, University of São Paulo Medical School, Sao Paulo, Brazil.
  • Kunz M; Bipolar Disorder Program and Laboratory of Molecular Psychiatry, National Institute for Translational Medicine, INCT-TM, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Young LT; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Lam RW; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Wong H; School of Population & Public Health, University of British Columbia, Vancouver, BC, Canada.
Mol Psychiatry ; 21(8): 1050-6, 2016 08.
Article em En | MEDLINE | ID: mdl-26460229
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzodiazepinas / Transtorno Bipolar / Risperidona Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzodiazepinas / Transtorno Bipolar / Risperidona Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article